FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	.C. 20549
---------------	-----------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Mohan Raju					2. Issuer Name and Ticker or Trading Symbol Ventyx Biosciences, Inc. [VTYX]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	,	,	st) (Middle) SCIENCES, INC.				3. Date of Earliest Transaction (Month/Day/Year) 04/05/2023								belov	er (give title v) Chief Execu	ıtive O	Other (s below) fficer	specify
662 ENCINITAS BLVD., STE. 250					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	TAS C	92024												X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication													
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													nded to
		Table	1 - 1	Non-Deriva	tive \$	Secu	rities	Acc	quire	ed, D	isposed o	of, or l	Benefic	ially	Own	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yes					2A. Deemed Execution Date, if any (Month/Day/Year)		, T	3. Transaction Code (Instr. 8) 4. Securities Disposed Of					Beneficia		ities icially d Following	6. Owner Form: I (D) or Indirect	Direct t (I)	7. Nature of Indirect Beneficial Ownership	
								С		v	Amount	(A) or (D)	Price		Transa	action(s) 3 and 4)	(Instr. 4	"	(Instr. 4)
Common Stock 04/05/202					3			S			10,165	D	\$29.607	71(2)	1,5	,592,961)	
Common Stock 04/05/202:					3			S ⁽¹⁾		3,065 D \$30.		\$30.490)9 ⁽³⁾	1,589,896		Γ			
Common Stock 04/06/2023				3			S			7,515	D	\$29.007	74 ⁽⁴⁾ 1,582		82,381	Γ			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any				ransaction of ode (Instr. Derivati		rative rities ired r osed)	Exp	iration	ny/Year) Securi Underl Deriva Securi 3 and 4		unt of rities erlying vative rity (Instr. d 4)	nt of ties ying (Institute ty (Instr. 1)		rice of ivative urity Securities Beneficiall Owned Following Reported Transactio (Instr. 4)		vnership rm: rect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	\v	(A)	(D)	Date Exercisat		Expiration e Date	n Title	of						

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2022.
- 2. Represents the weighted average share price of an aggregate total of 10,165 shares sold in the price range of \$29.00 to \$29.9994. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 3. Represents the weighted average share price of an aggregate total of 3,065 shares sold in the price range of \$30.0008 to \$30.835. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 4. Represents the weighted average share price of an aggregate total of 7,515 shares sold in the price range of \$29.00 to \$29.085. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

/s/ Christopher Krueger, as

04/07/2023

Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.